Sat 2/16/2019 16:24 ET
S&P 5002775.6030.251.09%BANKS441.7310.652.41%OIL55.811.402.51%BITCOIN3614.5220.960.58%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Idera Pharmaceuticals - IDRA)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add IDRA
From: singhtelecom (Rep: 959)Date: 01/22/2018 08:46
Forum: Wall Street Pit - Msg #2714718 - List IDRA msgs Thread #673984147 (Rec: 0)
A robust development pipeline, including 4 late stage programs that provide near-term commercial and partnering opportunities:
BCX7353 – Phase 3 program for the prophylactic treatment of Hereditary Angioedema (HAE) in a capsule formulation with FDA orphan drug designation
IMO-2125 – Phase 3 program for the treatment of PD1-refractory melanoma in combination with ipilimumab with FDA orphan drug designation
IMO-8400 – Phase 2 program for dermatomyositis
BCX7353 – Phase 2 program for the acute treatment of HAE in a liquid formulation
Proven leadership across commercial, development, scientific and clinical functions, providing a combination of management and scientific talent that marries the necessary ingredients for a successful, sustainable biotech company.
Synergistic discovery engines highlighted by two distinct research technologies and expertise which expands the number of rare disease therapeutic targets and candidates.
Financial strength with approximately $243 million net cash balance (unaudited proforma cash balance as of December 31, 2017), with opportunities to add further non-dilutive capital to fund internal clinical development efforts, commercial launch efforts, and continued business development activities.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnoreIDRA: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add IDRA | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999-, Inc.